Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax
Español  |  中國傳統的  |  简体中文
Call us  (855) 528-7322
Main Menu

Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax

Sponsor: George E. Peoples, Cancer Insight, LLC

Enrolling in our Bronx locations. A randomized, single-blinded, placebo-controlled Phase II trial of Herceptin + NeuVax vaccine + granulocyte macrophage-colony stimulating factor (GM-CSF) versus Herceptin + GM-CSF alone. The target study population is node-positive (NP) (or node-negative [NN] if negative for both ER and PR) breast cancer patients with HER2 1+ and 2+ expressing tumors who are disease-free after standard of care therapy.